

How immuno-oncology (PD-1/PD-L1 inhibitors) cancer treatments could impact patients and Australia's economy.

Immuno-oncology (IO) therapies are compared to standard of care for several types of cancer.³ They work by blocking proteins in the body called checkpoints. These checkpoints can sometimes stop the body's immune system from attacking cancer cells.

What is the impact of IO therapies on patients and society?

Immuno-oncology therapies have been shown to improve overall survival for several types of cancer.³ They work by blocking proteins in the body called checkpoints. These checkpoints can sometimes stop the body's immune system from attacking cancer cells.

Immuno-oncology therapies have been shown to improve overall survival for several types of cancer.³ They work by blocking proteins in the body called checkpoints. These checkpoints can sometimes stop the body's immune system from attacking cancer cells.

What are immuno-oncology (IO) therapies?

Immuno-oncology (IO) therapies are compared to standard of care for several types of cancer.³ They work by blocking proteins in the body called checkpoints. These checkpoints can sometimes stop the body's immune system from attacking cancer cells.

Immuno-oncology (IO) therapies are compared to standard of care for several types of cancer.³ They work by blocking proteins in the body called checkpoints. These checkpoints can sometimes stop the body's immune system from attacking cancer cells.

Immuno-oncology (IO) therapies are compared to standard of care for several types of cancer.³ They work by blocking proteins in the body called checkpoints. These checkpoints can sometimes stop the body's immune system from attacking cancer cells.

Impact of IO therapies on patients and society

Immuno-oncology (IO) therapies are compared to standard of care for several types of cancer.³ They work by blocking proteins in the body called checkpoints. These checkpoints can sometimes stop the body's immune system from attacking cancer cells.

- Add 0.5 life years for these Australian cancer patients – an increase of 1.5%
- Add 0.5 progression-free survival years – an increase of 1.5%

Progression-free means the time a patient lives with a cancer that doesn't get worse.

allowing them to contribute to their communities and the economy! If immuno-oncology therapies were used for all

<p>el atients to or more than an additional 20 million* hours.⁵</p>	<p>\$1.4 billion in atient roducti ity ~\$2 000 er atient .¹</p>	<p>\$40 million</p>	<p>Lower out-of-pocket costs for patients by \$28 million or 7.5%.[^]</p>	<p>Lower end-of-life costs by \$13000 a year per patient.[^]</p>

The equivalent of **2385 full-time people for 5 years** (35 hrs x ac)



While HIP 2.0 bows the costs to government for funding immuno-oncology

Government and industry must work together to improve access to immuno-oncology therapies.

- 01**

 - **Realise the ambition of the Australian Cancer Plan** will require new thinking about how to fund access to cutting-edge technologies in a sustainable way for patients and the health system.
- 02**

 - **Conduct a health technology assessment review** as outlined in the Medicines Australia Strategic Agreement.

msd-australia.com.au

Level 1, Building A, 26 Talavera Road, Macquarie Park NSW 2113. AU-NON-00476. Issued October 2021.



¹ Bates, N. et al. Labour force participation and the cost of lost productivity due to cancer in Australia. BMC Public Health 18, 375 (2018). <https://doi.org/10.1186/s12889-018-5297-9>. ³ Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 11, 3801 (2020). <https://doi.org/10.1038/s41467-020-17670-y> ⁴ National Cancer Institute. Immune Checkpoint Inhibitors. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor> Accessed September 2021. ⁵

*Based on full-time work = 35 hour per week x 48 weeks per annum (1,680 hours p.a.), over 2021-25 period. (20,038,202 hours/1,680/5 = 2,385)